DEFA14A8-K ·Filed Sep 14, 2026

ONCO

Onconetix, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed18d 9h ago SEC0001213900-26-099528
Actionable Insight • Neutral

This bridge loan is a procedural step to keep the target funded pre-close. The key catalyst remains the closing of the Realbotix acquisition, which requires shareholder and regulatory approvals. Monitor for the S-4 registration statement and proxy filing for vote timing.

DirectionNeutral
Confidencehigh
Horizonmonths
Latest settled — T+5d ⚠ clustered
ONCO ▲ +2.75% at T+5d
NEUTRAL call ✓ call won +2.75% · α vs SPY +2.64% · entry $0.6374 → $0.6549
Next anchor: T+20d in 9d
Latest observation: T+9 +51.45% FF3 residual α
Entry anchored
Sep 14, 10:41 AM ET
via 1-min bar
T+1d
+1.22%
call +1.22% · α +1.68%
$0.6452
settled 18d ago
T+5d
+2.75%
call +2.75% · α +2.64%
$0.6549
settled 12d ago
T+20d
—
call — · α —
—
in 9d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

Onconetix (ONCO) entered into a Grid Promissory Note to lend Realbotix LLC up to $5.0 million, with an initial $2.5 million advance, to support the target's working capital ahead of Onconetix's pending all-stock acquisition of Realbotix. The non-interest-bearing note is automatically cancelled upon closing of the Share Exchange Agreement, and the outstanding principal plus $500,000 reduces the cash Onconetix needs at closing. This is a routine bridge financing step in an ongoing M&A process, not a standalone catalyst for ONCO's stock.

Key Financial Metrics

Deal Type
other

Key Facts

  • Onconetix agreed to lend Realbotix LLC up to $5.0 million via a Grid Promissory Note dated September 11, 2026.
  • An initial advance of $2.5 million was funded on September 11, 2026.
  • The note is unsecured, matures September 11, 2027, and is non-interest bearing before the closing or termination of the Share Exchange Agreement.
  • Upon closing of the acquisition, the note is automatically cancelled and the Net Cash at Closing is increased by $500,000 plus the outstanding principal.
  • The acquisition closing condition requires Onconetix to have at least $12.5 million in Net Cash at closing.
  • Realbotix Corp. guarantees the note, and the guarantee is subject to TSX Venture Exchange acceptance.

Financial Impact

Onconetix is deploying up to $5.0M of its cash to fund Realbotix's working capital; this reduces Onconetix's cash available for the $12.5M Net Cash closing condition, effectively recycling the loan back into the closing cash requirement.

cashdebtnet cash at closing

Risk Factors

  • If the Realbotix acquisition fails to close, Onconetix holds an unsecured $2.5M+ note from Realbotix with 12% interest, creating credit risk.
  • The $2.5M advance reduces Onconetix's cash reserves, potentially straining its own operations if the deal is delayed or terminated.
  • The acquisition closing condition of $12.5M Net Cash may be harder to satisfy if additional advances are drawn.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 15 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (ONCO) — Batch item 10001213900-26-099528
Document: ea030515701ex10-2.htm0001213900-26-099524
Document: ea0305157-8k_onconetix.htm0001213900-26-099528
Document: ea030515701ex99-1.htm0001213900-26-099528
Document: 0001213900-26-099528-index-headers.html0001213900-26-099528
Document: 0001213900-26-099528-index.html0001213900-26-099528
Document: 0001213900-26-099528.txt0001213900-26-099528
8-K Filing (ONCO) — Batch item 80001213900-26-099524
Document: ea030515701ex10-2.htm0001213900-26-099528
Document: ea0305157-8k_onconetix.htm0001213900-26-099528
Document: ea030515701ex99-1.htm0001213900-26-099528
Document: 0001213900-26-099524-index-headers.html0001213900-26-099528
Document: 0001213900-26-099524-index.html0001213900-26-099528
Document: 0001213900-26-099524.txt0001213900-26-099528
DEFA14A Filing (ONCO) — Batch item 150001213900-26-099528
22 reports for ONCO
Performance horizon
67% Hit rate 8 of 12 directional calls best @ T+60▲ +78.04%May 8, 2026
Filters
Rows
Reports for ONCO — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
DEFA14A / 8-K
NEUTRAL ★ 4/10
$0.6374 $0.6549▲ +2.75%▲ +2.64%$0.7440 (+16.72%)
Sep 14, 2026
18d ago
8-K
BEARISH ★ 6/10
$0.6374 $0.6549▼ −2.75%▼ −2.64%$0.7440 (−16.72%)
Sep 14, 2026
18d ago
425
BEARISH ★ 6/10
$0.6374 $0.6549▼ −2.75%▼ −2.64%$0.7440 (−16.72%)
Sep 4, 2026
28d ago
EFFECT
BEARISH ★ 8/10
$1.02 $0.6374▲ +37.51%▲ +36.30%$0.7440 (+27.06%)
Sep 3, 2026
29d ago
425
NEUTRAL ★ 3/10
$0.7390 $0.7564▲ +2.35%▲ +3.50%$0.7440 (+0.68%)
Aug 31, 2026
4w ago
S-1/A
BEARISH ★ 8/10
$0.6528 $0.8132▼ −24.57%▼ −24.49%$0.7440 (−13.97%)
Aug 12, 2026
7w ago
S-1
BEARISH ★ 8/10
$0.8920 $0.7110▲ +20.29%▲ +19.85%$0.7440 (+16.59%)
Jul 29, 2026
9w ago
8-K
BEARISH ★ 8/10
$0.7864 $0.9037▼ −14.92%▼ −11.29%$0.7440 (+5.39%)
Jul 7, 2026
12w ago
425
NEUTRAL ★ 2/10
$1.07 $0.8487▼ −20.68%▼ −21.23%$0.7440 (−30.47%)
Jun 17, 2026
15w ago
EFFECT
BEARISH ★ 6/10
$0.9949 $1.00▼ −0.51%▼ −1.55%$0.7440 (+25.22%)
Showing 10 of 22

US Market Status

Market Closed — Opens Mon (37h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access